CROI 2026 - CROI 2026

Oral Abstract: Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions

"Increased Risk of Heart Failure With Preserved Ejection Fraction in South Africans With HIV" by Zaayid Omar University of Cape Town, Cape Town, South Africa

Oral Abstract: Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions

"Relationship of Inflammatory, Cardiac, and Lipid Biomarkers to Cardiovascular Events in REPRIEVE" by Steven Grinspoon Massachusetts General Hospital, Boston, MA, USA

Oral Abstract: Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions

"Incident Hypertension in REPRIEVE: Risk Factors, Pitavastatin Effect & Cardiovascular Consequences" by Esteban Martinez Hospital Clinic of Barcelona, Barcelona, Spain

Oral Abstract: Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions

"Population-Level Obesity Trends by HIV Status in Pre-/Post-DTG Era in Rural East Africa SEARCH Study" by Elijah R. Kakande Infectious Disease Research Collaboration, Kampala, Uganda

Oral Abstract: Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions

"Questions and Answers (Part 1)" by

Oral Abstract: Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions

"Weight Rebound After Discontinuing Metformin in PWH Without Diabetes: Week 144 Trial Results" by Cristina Marcelo Calvo La Paz University Hospital, Madrid, Spain

Oral Abstract: Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions

"Rates and Risk Factors for Oropharyngeal Squamous Cell Carcinoma Among People Living With HIV" by Antonio Bandala-Jacques The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Oral Abstract: Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions

"Kaposi Sarcoma Herpesvirus in Plasma: Association With Treatment Failure in Limited-Stage AIDS-KS" by Dirk P. Dittmer University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Oral Abstract: Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions

"Intensification of Tuberculosis Treatment in Severely Immunocompromised Individuals With HIV" by François-Xavier Blanc University Hospital of Nantes, Nantes, France

Oral Abstract: Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions

"Adjunctive Prednisone for Inpatients With Disseminated HIV-Associated TB" by Phiona E. Namale University of Cape Town, Cape Town, South Africa

Oral Abstract: Beyond the Virus: The Expanding Landscape of HIV-Associated Conditions

"Questions and Answers (Part 2)" by

Oral Abstract: From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP

"Introduction of Speakers (Part 1)" by

Oral Abstract: From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP

"Implants Releasing NRTTI MK-8591 Fail to Protect Macaques Against SHIV Containing the M184V Mutation" by Charles Dobard Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP

"MK-8527 Phase III Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis" by Yash Kapoor Merck Sharp & Dohme, Rahway, NJ, USA

Oral Abstract: From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP

"Final Results of the ANRS PREVENIR Study With Daily or On-Demand Oral PrEP With TDF/FTC in Paris" by Jean-Michel Molina Assistance Publique – Hôpitaux de Paris, Paris, France

Oral Abstract: From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP

"Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1" by Nkosiphile Ndlovu Wits Reproductive Health and HIV Institute, Johannesburg, South Africa

Oral Abstract: From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP

"Questions and Answers (Part 1)" by

Oral Abstract: From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP

"Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase" by Valeria D. Cantos Lucio Emory University, Atlanta, GA, USA

Oral Abstract: From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP

"Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase" by Stephanie Cox Gilead Sciences, Inc, Foster City, CA, USA

Oral Abstract: From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP

"RCT of Dynamic Choice to Provide Oral PrEP to Postpartum South African Women" by Dvora L. Joseph Davey University of California Los Angeles, Los Angeles, CA, USA

Oral Abstract: From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP

"Effect of Different Pharmacy PrEP Delivery Models on Initiation and Continuation in Kenya: A cRCT" by Katrina F. Ortblad Fred Hutchinson Cancer Center, Seattle, WA, USA

Oral Abstract: From Breakthroughs to Backbones: The Evolving Landscape of HIV PrEP

"Questions and Answers (Part 2)" by

Oral Abstract: Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging

"Impact of Elevated S100A8/A9 and Classical Monocytes on Cerebrovascular Dysfunction in Long COVID" by Meera V. Singh University of Rochester Medical Center, Rochester, NY, USA

Oral Abstract: Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging

"Shared Microglia Subtypes in Brain and CSF Reveal HIV-Driven Immune Dysregulation" by Paraskevas Filippidis Yale University, New Haven, CT, USA

Oral Abstract: Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging

"Characterization of HIV Proviruses in Brain Microglia in PWH on ART" by Alana N. Thomas National Cancer Institute at Frederick, Frederick, MD, USA

Oral Abstract: Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging

"Tryptophan Metabolomic Profiling in Persons With and Without HIV: Associations With CNS Outcomes" by Alan Winston Imperial College London, London, UK

Oral Abstract: Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging

"Questions and Answers (Part 1)" by

Oral Abstract: Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging

"Introduction of Speakers (Part 2)" by

Oral Abstract: Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging

"Effects of Low-Dose Hydrocortisone on Cognition in Women With HIV: A Placebo-Controlled Trial" by Leah Rubin The John Hopkins University, Baltimore, MD, USA

Oral Abstract: Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging

"Multimodal PET Imaging Reveals Focal HIV Activity and Immune Activation During ATI Prior to Rebound" by Timothy J. Henrich University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging

"Targeting Mucosal Immunity Through Fc-Engineered Broadly Neutralizing Antibodies" by Claudia Stroupe Northwestern University, Chicago, IL, USA

Oral Abstract: Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging

"GLP-1 RA Induces Gut T-Cell and Epithelial Remodeling in PWH From a Clinical Trial in South Africa" by Miguel Marin Africa Health Research Institute, Durban, South Africa

Oral Abstract: Frontiers in Neuropathogenesis and Tissue Biology: Decoded Through Cellular Dynamics, Metabolics, and Imaging

"Questions and Answers (Part 2)" by

Oral Abstract: Interaction of HIV With Cells and People

"Structural and Mechanistic Bases for Encapsulation of Ribonucleoprotein Complexes Inside HIV-1 Cores" by Mamuka Kvaratskhelia University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Oral Abstract: Interaction of HIV With Cells and People

"Molecular and Structural Determinants of MDA5 Sensing of HIV-1 Unspliced RNA" by Hisashi Akiyama Boston University, Boston, MA, USA

Oral Abstract: Interaction of HIV With Cells and People

"RNA m6A Modification Confers HIV Replication Fitness and Resistance to Type-I Interferon" by Jonathan Karn Case Western Reserve University, Cleveland, OH, USA

Oral Abstract: Interaction of HIV With Cells and People

"Species-Specific APOBEC3G mRNA Splicing Drives Divergent HIV Versus SIV Hypermutation Landscapes" by Armando D. Mendez Texas Biomedical Research Institute, San Antonio, TX, USA

Oral Abstract: Interaction of HIV With Cells and People

"Questions and Answers (Part 1)" by

Oral Abstract: Interaction of HIV With Cells and People

"Genome-Wide HIV-Guided CRISPR Screen Identifies Novel Antiviral Factors Including Targets of Vpu" by Guillermo Gosálbez Ulm University Medical Center, Ulm, Germany

Oral Abstract: Interaction of HIV With Cells and People

"Systematic Discovery of Pro- and Anti-HIV Host Factors in Primary Human CD4+ T Cells" by Eli Dugan University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Interaction of HIV With Cells and People

"Defective HIV-1 Proviruses Express Env and Contribute to Soluble gp120 in the Plasma of PWH on ART" by Mehdi Benlarbi Université de Montréal, Montreal, Canada

Oral Abstract: Interaction of HIV With Cells and People

"Sex-Specific Differences in HIV Replication and Inflammation in the Rectal Explant Challenge Model" by Stacey A. Smith Emory University, Atlanta, GA, USA

Oral Abstract: Interaction of HIV With Cells and People

"Questions and Answers (Part 2)" by

Oral Abstract: HIV Reservoirs and Cure Strategies

"A Posttranscriptional Block Limits HIV Env Expression in Reactivated Cells From PWH on ART" by Jonathan Richard Centre de Recherche du CHUM, Montreal, Canada

Oral Abstract: HIV Reservoirs and Cure Strategies

"Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B" by Julia Edgar University of Oxford, Oxford, UK

Oral Abstract: HIV Reservoirs and Cure Strategies

"Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control" by Katie Fisher Aarhus University, Aarhus, Denmark

Oral Abstract: HIV Reservoirs and Cure Strategies

"Bacteria-Specific CD4+ T Cells Contribute to HIV Persistence During ART" by Armando Espinosa Ortiz Université de Montréal, Montreal, Canada

Oral Abstract: HIV Reservoirs and Cure Strategies

"Questions and Answers (Part 1)" by

Oral Abstract: HIV Reservoirs and Cure Strategies

"CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption" by Jeffrey Murry Gilead Sciences, Inc, Foster City, CA, USA

Oral Abstract: HIV Reservoirs and Cure Strategies

"Decoding the Somatic Mutation Landscape in Persisting HIV-1-Infected CD4+ T Clones" by Marie Armani-Tourret Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: HIV Reservoirs and Cure Strategies

"Ibalizumab-Targeted Delivery of Tat mRNA Transactivates Provirus Expression In Vivo" by Edward F. Kreider University of Pennsylvania, Philadelphia, PA, USA

Oral Abstract: HIV Reservoirs and Cure Strategies

"Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT" by Ana Gabriela Pires Dos Santos AbbVie, Inc, North Chicago, IL, USA

Oral Abstract: HIV Reservoirs and Cure Strategies

"Questions and Answers (Part 2)" by

Oral Abstract: Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care

"DOLPHIN-KIDS: Phase I/II Trial of Dolutegravir With 3HP for TB Prevention in Children With HIV" by Nicole Salazar-Austin The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Oral Abstract: Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care

"Empiric Valganciclovir Reduces Mortality in Infants Living With HIV and Severe Pneumonia" by Pablo Rojo Fundación para la Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain

Oral Abstract: Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care

"Viral Control Among Children in Botswana Receiving Combination Broadly Neutralizing Antibodies" by Gbolahan Ajibola Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana

Oral Abstract: Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care

"Very Early ART Initiation Associated With Sustained Aviremia in Time-to-Rebound Pediatric ATI" by Gabriela Z. L. Cromhout University of KwaZulu-Natal, Durban, South Africa

Oral Abstract: Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care

"Questions and Answers (Part 1)" by

Oral Abstract: Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care

"DTG/3TC Is Noninferior to DTG-Based 3-Drug ART in Children With HIV: D3/Penta 21 Week-96 Results" by Anna Turkova MRC Clinical Trials Unit at UCL, London, UK

Oral Abstract: Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care

"Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End-of-Study Results" by Aditya Gaur St Jude Children's Research Hospital, Memphis, TN, USA

Oral Abstract: Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care

"Improved Viral Suppression and Retention: Randomized Trial of an Adolescent Transition Intervention" by Brian Zanoni Emory University, Atlanta, GA, USA

Oral Abstract: Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care

"Immunogenicity of 2- Versus 3-Dose HPV Vaccination by HIV Infection Status in Eswatini" by Harriet Nuwagaba-Biribonwoha ICAP at Columbia University, New York, NY, USA

Oral Abstract: Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care

"Questions and Answers (Part 2)" by

Oral Abstract: Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer

"Efficacy and Safety of BLV 2 or 10 mg in CHD Including Patients With HIV/HBV: MYR301 Final Results" by David Wyles Denver Health Medical Center, Denver, CO, USA

Oral Abstract: Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer

"Hepatitis B Reactivation/Infection in People With HIV on Tenofovir-Sparing Antiretroviral Therapy" by Grace Haser University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer

"Long-Term Outcomes of Liver Transplant Recipients Living With HIV: A Multicenter Case-Control Study" by José M. Miró Hospital Clinic of Barcelona, Barcelona, Spain

Oral Abstract: Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer

"Early Detection of HCC via Active Surveillance in Persons With HIV in Uganda at High Risk" by Katuku Jim Aizire The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Oral Abstract: Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer

"Questions and Answers (Part 1)" by

Oral Abstract: Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer

"One-Month Versus 3-Month Rifapentine-Based Tuberculosis Preventive Therapy in People With HIV" by Anchalee Avihingsanon Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Oral Abstract: Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer

"Twice-Daily Dolutegravir With a 4-Month Rifapentine-Based Regimen for HIV-Associated Tuberculosis" by Sean Wasserman St George's University of London, London, UK

Oral Abstract: Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer

"DOLPHIN-Moms: Pharmacokinetics and HIV Suppression With Once-Daily Dolutegravir and 3HP in Pregnancy" by Jyoti S. Mathad Weill Cornell Medicine, New York, NY, USA

Oral Abstract: Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer

"Safety and Treatment Completion of 1HP Versus 3HP in People With HIV: The One-to-Three Trial" by Jayajothi Moodley The Aurum Institute, Johannesburg, South Africa

Oral Abstract: Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer

"Novel Linezolid Dosing With Bedaquiline, Delamanid, and Clofazimine for Drug-Resistant TB Treatment" by Constance A. Benson University of California San Diego, La Jolla, CA, USA

Oral Abstract: Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer

"Questions and Answers (Part 2)" by

Oral Abstract: We Thought You'd Never Ask: Improving HIV Screening and Testing

"Cluster-Randomized Stepped-Wedge Trial of HIV Rapid Testing and Risk Assessment in Primary Care" by Maria Jesus Perez Elias Ramon y Cajal Hospital, Madrid, Spain

Oral Abstract: We Thought You'd Never Ask: Improving HIV Screening and Testing

"Enhanced Opt-Out HIV Screening & Linkage to Care for 216K Patients at 13 Community Health Centers" by Timothy Long MD Health Choice Network, Miami, FL, USA

Oral Abstract: We Thought You'd Never Ask: Improving HIV Screening and Testing

"Electronic Health Record-Driven Universal HIV Screening and Missed Opportunities in Southeastern US" by David E. Hudon Prisma Health, Greenville, SC, USA

Oral Abstract: We Thought You'd Never Ask: Improving HIV Screening and Testing

"Using Machine Learning to Optimize HIV Risk Prediction and Case Identification in Eastern Kenya" by Peter Kyalo Center for International Health, Education and Biosecurity (CIHEB) Kenya, Nairobi, Kenya

Oral Abstract: We Thought You'd Never Ask: Improving HIV Screening and Testing

"Questions and Answers (Part 1)" by

Oral Abstract: We Thought You'd Never Ask: Improving HIV Screening and Testing

"Global Analysis of HIV Oral PrEP-to-Need Ratios (PnR) in 2025" by Andrew Hill University of Liverpool, Liverpool, UK

Oral Abstract: We Thought You'd Never Ask: Improving HIV Screening and Testing

"The Impact of SEARCH Community Precision Health on HIV Incidence in Rural Kenya and Uganda" by Gabriel Chamie University of California San Francisco, San Francisco, CA, USA

Oral Abstract: We Thought You'd Never Ask: Improving HIV Screening and Testing

"Urine Tenofovir and POC Viral Load Testing After ART Start: Week 72 Outcomes of STREAM-HIV Trial" by Paul K. Drain University of Washington, Seattle, WA, USA

Oral Abstract: We Thought You'd Never Ask: Improving HIV Screening and Testing

"Evaluating the Viability of Self-Collected Blood for Remotely Testing HIV Suppression Among MSM" by Jeffrey Johnson Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: We Thought You'd Never Ask: Improving HIV Screening and Testing

"Questions and Answers (Part 2)" by

Oral Abstract: Extending the Reach: Long-Acting Antiviral and Novel Delivery

"Safety, Pharmacokinetics, and Antiviral Activity of GS-3242, a Novel Long-Acting Injectable InSTI" by Samir Gupta Indiana University Health, Indianapolis, IN, USA

Oral Abstract: Extending the Reach: Long-Acting Antiviral and Novel Delivery

"Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing" by Nilay Thakkar GSK plc, Collegeville, PA, USA

Oral Abstract: Extending the Reach: Long-Acting Antiviral and Novel Delivery

"Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184" by Hyunmoon Back GSK plc, Collegeville, PA, USA

Oral Abstract: Extending the Reach: Long-Acting Antiviral and Novel Delivery

"DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study" by Juergen K. Rockstroh Bonn University Hospital, Bonn, Germany

Oral Abstract: Extending the Reach: Long-Acting Antiviral and Novel Delivery

"Questions and Answers (Part 1)" by

Oral Abstract: Extending the Reach: Long-Acting Antiviral and Novel Delivery

"Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study" by Charlotte-Paige Rolle Orlando Immunology Center, Orlando, FL, USA

Oral Abstract: Extending the Reach: Long-Acting Antiviral and Novel Delivery

"Safety and Antiviral Effect of 10E8.4/Ibalizumab in People With HIV: A Phase Ib Trial" by Trevor A. Crowell Henry M Jackson Foundation, Bethesda, MD, USA

Oral Abstract: Extending the Reach: Long-Acting Antiviral and Novel Delivery

"Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks" by Pablo Tebas University of Pennsylvania, Philadelphia, PA, USA

Oral Abstract: Extending the Reach: Long-Acting Antiviral and Novel Delivery

"Phase III Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1" by Chloe M. Orkin Queen Mary University of London, London, UK

Oral Abstract: Extending the Reach: Long-Acting Antiviral and Novel Delivery

"Questions and Answers (Part 2)" by

Oral Abstract: From Good to Great: Advancing Treatment and Prevention

"HIV Testing and Treatment Gaps in Subgroups of Men With HIV: Insights From 7 African countries" by Craig J. Heck Columbia University Irving Medical Center, New York, NY, USA

Oral Abstract: From Good to Great: Advancing Treatment and Prevention

"Impact of Person-Centered Care Intervention on HIV Treatment Failure Response in Zambia" by Kombatende Sikombe Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

Oral Abstract: From Good to Great: Advancing Treatment and Prevention

"The START mHealth Application Reduces Risk of Virologic Rebound in Men With HIV Who Use Stimulants" by Adam W. Carrico Florida International University, Miami, FL, USA

Oral Abstract: From Good to Great: Advancing Treatment and Prevention

"Effects of a Coping Intervention on Viral Load Among South African Women With HIV and Sexual Trauma" by Kathleen J. Sikkema Columbia University, New York, NY, USA

Oral Abstract: From Good to Great: Advancing Treatment and Prevention

"Questions and Answers (Part 1)" by

Oral Abstract: From Good to Great: Advancing Treatment and Prevention

"SMART ART: A Randomized Clinical Trial of Adaptive Strategies for HIV Viral Suppression in S Africa" by Ruanne V. Barnabas Massachusetts General Hospital, Boston, MA, USA

Oral Abstract: From Good to Great: Advancing Treatment and Prevention

"Early Findings From Cabotegravir Injectable HIV PrEP Rollout in Malawi: Uptake and Continuation" by Deborah Hoege Georgetown University, Washington, DC, USA

Oral Abstract: From Good to Great: Advancing Treatment and Prevention

"Randomised Pilot of Pharmacy-Based Collection of PrEP Refills Among Female Sex Workers in Zimbabwe" by Constancia C. Watadzaushe Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe

Oral Abstract: From Good to Great: Advancing Treatment and Prevention

"Integrating HIV and Hypertension Care Improves Blood Pressure in Uganda: A Cluster Randomized Trial" by Chris T. Longenecker University of Washington, Seattle, WA, USA

Oral Abstract: From Good to Great: Advancing Treatment and Prevention

"Questions and Answers (Part 2)" by

Oral Abstract: Manipulating the HIV Immune Response for Prevention and Treatment

"Autologous Functional Antibody Dynamics in the Context of bNAb Therapy for HIV" by Boris Juelg Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: Manipulating the HIV Immune Response for Prevention and Treatment

"Autologous Monoclonal Neutralizing Antibodies as a Promising Path to a Functional HIV-1 Cure" by Junlin Zhuo The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Oral Abstract: Manipulating the HIV Immune Response for Prevention and Treatment

"In Vivo HSC Gene Therapy Drives Sustained eCD4-Ig Expression Primarily by B-Cells for SIV Prevention" by John K. Bui Fred Hutchinson Cancer Center, Seattle, WA, USA

Oral Abstract: Manipulating the HIV Immune Response for Prevention and Treatment

"Shared Resistance Pathways to CD4bs bNAbs Between Viremic SHIV NHP Model and Human Clinical Trials" by Jiajie Li University of Pennsylvania, Philadelphia, PA, USA

Oral Abstract: Manipulating the HIV Immune Response for Prevention and Treatment

"Questions and Answers (Part 1)" by

Oral Abstract: Manipulating the HIV Immune Response for Prevention and Treatment

"Assessing Early Immune Response to HIV Rebound in Viremic Controllers and Noncontrollers" by Anna Farrell-Sherman Fred Hutchinson Cancer Center, Seattle, WA, USA

Oral Abstract: Manipulating the HIV Immune Response for Prevention and Treatment

"A Conserved NK-Like KIR+ CD8+ T-Cell Subset Mediates Exceptional HIV Control and Functional HBV Cure" by Gaurav Gaiha Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: Manipulating the HIV Immune Response for Prevention and Treatment

"Innate Immune Imprints Shape HIV-1 Reservoir Cell Persistence During Long-Term ART" by Toong Seng Tan Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: Manipulating the HIV Immune Response for Prevention and Treatment

"Repeated IL-10/PD-1 Blockades Potently Control SIV Rebound and Limit Reservoir in the Absence of ART" by Mirko Paiardini Emory University, Atlanta, GA, USA

Oral Abstract: Manipulating the HIV Immune Response for Prevention and Treatment

"Questions and Answers (Part 2)" by

Oral Abstract: Partners, Pills, and Penicillin: Progress in Prevention

"Declining HIV Incidence and Differential PrEP Effectiveness Among Key Populations With STIs, 2014-25" by Chase A. Cannon University of Washington, Seattle, WA, USA

Oral Abstract: Partners, Pills, and Penicillin: Progress in Prevention

"HIV Incidence Could Rise by 73% in 30 States if Ryan White Ends: A Simulation Study" by Melissa Schnure The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Oral Abstract: Partners, Pills, and Penicillin: Progress in Prevention

"HIV Incidence in a Nationwide Cohort of Transgender Women in the United States and Puerto Rico" by Sari L. Reisner University of Michigan, Ann Arbor, MI, USA

Oral Abstract: Partners, Pills, and Penicillin: Progress in Prevention

"Awareness of Sex Partners’ HIV Status and Risk of HIV Acquisition: Rakai, Uganda" by Victor Ssempijja Leidos Biomedical Research, Inc, Frederick, MD, USA

Oral Abstract: Partners, Pills, and Penicillin: Progress in Prevention

"Questions and Answers (Part 1)" by

Oral Abstract: Partners, Pills, and Penicillin: Progress in Prevention

"Comparative Effectiveness of 3 Benzathine Penicillin G-Based Regimens in PWH With Early Syphilis" by Kai Hsiang Chen National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan

Oral Abstract: Partners, Pills, and Penicillin: Progress in Prevention

"Early Syphilis and HIV Among Adolescents: United States, 20142-023" by Daniel Gore Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: Partners, Pills, and Penicillin: Progress in Prevention

"Pritelivir for Refractory HSV Infections in Immunocompromised Patients: Results of a Phase III Trial" by Jean-Michel Molina Assistance Publique – Hôpitaux de Paris, Paris, France

Oral Abstract: Partners, Pills, and Penicillin: Progress in Prevention

"Meningococcal B (4CMenB) Vaccination for the Prevention of Gonorrhea in Men Who Have Sex With Men" by Kate L. Seib Griffith University, Southport, Australia

Oral Abstract: Partners, Pills, and Penicillin: Progress in Prevention

"Questions and Answers (Part 2)" by